Boehringer Ingelheim GmbH is to pay €1.18 billion to acquire NBE-Therapeutics GmbH, a Swiss developer of antibody-drug conjugates (ADCs), in order to expand its portfolio of drugs targeting difficult-to-treat solid tumours. NBE-Therapeutics’ lead compound NBE-002 is currently in Phase 1 clinical studies for triple negative breast cancer, an aggressive form of breast cancer with limited treatment options.
